Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

MediciNova and Zhejiang Medicine to Set Up China JV for Asthma Drug

publication date: Mar 4, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
MediciNova Inc of San Diego has signed a letter of intent with Zhejiang Medicine Co. to set up a joint venture that will develop MediciNova’s asthma drug candidate in China. MN-221 is targeted to treat acute exacerbations of asthma or COPD that do not respond to normal bronchodilator or corticosteroid therapy. Terms of the JV were not disclosed. More details....

Stock Symbols: (NSDQ: MNOV) (JASDQ: 4875)  (SHA: 600216)

Share this with colleagues:  

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...